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Abstract
Background: Schizophrenia is associated with rare copy-number (CN) mutations. Screening for such alleles
genome-wide, though comprehensive, cannot study in-depth the causality of particular loci, therefore cannot
provide the functional interpretation for the disease etiology. We hypothesized that CN mutations in the SELENBP1
locus could associate with the disorder and that these mutations could alter the gene product’s activity in patients.
Methods: We analyzed SELENBP1 CN variation (CNV) in blood DNA from 49 schizophrenia patients and 49 controls
(cohort A). Since CN of genes may vary among tissues, we investigated SELENBP1 CN in age- sex- and postmortem
interval-matched cerebellar DNA samples from 14 patients and 14 controls (cohort B). Since CNV may either be de-
novo or inherited we analyzed CNV of the SELENBP1 locus in blood DNA from 26 trios of schizophrenia probands
and their healthy parents (cohort C). SELENBP1 mRNA levels were measured by real-time PCR.
Results: In cohort A reduced CN of the SELENBP1 locus was found in four patients but in none of the controls. In
cohort B we found reduced CN of the SELENBP1 locus in two patients but in none of the controls. In cohort C
three patients exhibited drastic CN reduction, not present in their parents, indicating de-novo mutation. A
reduction in SELENBP1 mRNA levels in the postmortem cerebellar samples of schizophrenia patients was found.
Conclusions: We report a focused study of CN mutations in the selenium binding-protein1 (SELENBP1) locus
previously linked with schizophrenia. We provide evidence for recurrence of decreased CN of the SELENBP1 locus
in three unrelated patients’ cohorts but not in controls, raising the possibility of functional involvement of these
mutations in the etiology of the disease.
Background
Genomic deletion, duplication and insertion, designated
copy number variation (CNV), are found in all human
beings, could be either common, rare or de novo [1]
and may influence gene expression and phenotypic var-
iation [2-6]. CNV have been linked to the pathogenesis
of both monogenic and complex disorders [7-13] includ-
ing brain-related disorders such as schizophrenia
[14-17]. Specifically, twenty five percent of subjects car-
rying a 3-Mb microdeletion in chromosome 22q11.2
exhibited psychiatric manifestations including autism,
attention-deficit hyperactivity disorder (ADHD) and
schizophrenia [18]. Recent whole genome CNV screens
revealed significant association of rare CNVs in several
loci with schizophrenia [16,19-21]. Confirmed de novo
CNV mutations were significantly associated with schi-
zophrenia and were about eight times more frequent in
sporadic (but not in familial) cases of schizophrenia as
compared to unaffected controls [21]. These findings
suggest that CNVs in certain loci are more prevalent in
schizophrenia patients as compared to controls.
Chromosome 1q21.3 harbors known CNVs in the gen-
eral population [3,5,22,23]. Interestingly, the 1q21-22
region has been reported to be linked with schizophre-
nia with a likelihood of linkage (LOD) score of 6.5
(Brzustowicz and others, 2000). The gene encoding sele-
nium binding protein (SELENBP)1 which has been
mapped to this region has recently been reported to be
associated with schizophrenia [24]. Moreover,
SELENBP1 mRNA levels were up-regulated in postmor-
tem brain and in blood cells from schizophrenia patients
[25,26]. Indeed, selenium is implicated in neuroprotec-
tion [27-32] and selenium deficiency has been reported
* Correspondence: dmishmar@bgu.ac.il; galila@bgu.ac.il
1Psychiatry Research Unit, Faculty of Health Sciences, Ben-Gurion University
of the Negev, and Mental Health Center, Beersheva, Israel
2Department of Life Sciences and National Institute of Biotechnology (NIBN),
Ben-Gurion University of the Negev, Beer Sheva, Israel
Amar et al. Behavioral and Brain Functions 2010, 6:40
http://www.behavioralandbrainfunctions.com/content/6/1/40
© 2010 Amar et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
to be associated with increased schizophrenia rates [33].
We therefore hypothesized that CNV including the
SELENBP1 locus is associated with schizophrenia. To
this end we compared blood DNA from schizophrenia
patients with healthy controls originating from the same
ethnicity group. Since CNV varies among tissues [34,35]
we then studied SELENBP1 CNV in postmortem cere-
bellum of schizophrenia patients and unrelated matched
controls. Among other brain regions the cerebellum has
also been implicated as involved in the pathophysiology
of schizophrenia [36,37]. Since CNV may either be
de novo or inherited [1] we further analyzed CNV of the
SELENBP1 gene in trios of schizophrenia probands and
their healthy parents in whole blood DNA. In order to
find out whether CNV in the SELENBP1 locus associ-
ates with the previously reported up-regulation of brain
SELENBP1 in schizophrenia, we measured SELENBP1
mRNA levels in the same postmortem cerebellar speci-
mens studied for CNV.
Materials and methods
Patient cohorts
Discovery cohort: Blood DNA samples from 49 unre-
lated schizophrenia patients and 49 healthy controls
originated from the Bedouins of the Negev population.
The samples from the patient group and from the nor-
mal controls were collected for separate previously
described studies after informed consent [38-40]. The
original protocols were approved by the Helsinki com-
mittee (Beer-Sheva). Another cohort was age- sex- and
postmortem interval-matched cerebellar samples from
14 schizophrenia patients and 14 matched normal con-
trols were obtained from the Victoria Brain Tissue
Repository at the Mental Health Research Institute of
Victoria, Melbourne, Australia. Their detailed demo-
graphic data are summarized in Table 1. Permission to
carry out studies was obtained from the Ethics Com-
mittee of the Victoria Institute of Forensic Medicine
and the North Western Mental Health Program Beha-
vioural and Psychiatric Research and Ethics Commit-
tee. An unrelated replication cohort of 78 blood DNA
samples from 26 unrelated schizophrenia patients and
their healthy parents originated from Israeli Arabs
recruited for previously described studies after
informed consent [41,42]. The original protocol was
approved by the Helsinki committee (Beer-Sheva). All
samples of the three cohorts became de-identified
prior to our study.
DNA purification
DNA for the dertermination of CNV was extracted from
whole blood using standard techniques (Phenol-chloro-
form). DNA concentration and quality was quantified
using a Nanodrop ND-1000 spectrophotometer
(Nanodrop Technologies, Wilmington, DE). DNA con-
centration was brought to 50 ng/μl for the SELENBP1
amplification and to 5 ng/μl for the Factor 8 (F8, a gene
locus lacking CNV) amplification.
RNA purification and cDNA synthesis
For the determination of SELENBP1 mRNA levels RNA
purification, determination of purity and concentration
and cDNA synthesis were carried out as previously
described [43].
Measurement of DNA copy number by real time PCR
Quantitative PCR was performed using the F8 gene
locus as a reference for normalization of the real time
PCR experiments. This gene was chosen since it does
not exhibit CNV [44]. F8 forward (CTACCATC-
CAGGCTGAGGTTTATG) and reverse (CACCAA-
CAGCATGAAGACT GACA) primers were used as
previously described [44]. A fragment of 254 bp of exon
12 of the SELENBP1 gene was amplified using the for-
ward (CCACCAGGGAAGGCTCTGTGA) and reverse
(GGGTGCCAAGAGAGAGCAGAA) primers designed
using the program OLIGO and based on the published
DNA sequence in Genbank (NM_003944).
Real-time quantitative PCR was performed using
Rotor Gene 3000 (Corbett Research, Sydney, Australia).
Reactions were carried out in a final volume of 25 μl
consisting of either 50 ng/μl for the SELENBP1 ampli-
fication or 5 ng/μl for Factor 8 amplification, 250 nM
forward and reverse primers each and 12.5 μl ABsolute
QPCR SYBR Green Mix (ABgene, Surrey, UK) includ-
ing dNTPs, Taq DNA polymerase and reaction buffer.
Real-time PCR assays of SELENBP1 and F8 CNV
included an initial step of 15 min at 95°C to activate
Taq polymerase, followed by 40 cycles comprising
denaturing at 95°C for 15 sec, annealing at 58.8°C for
20 seconds and extension at 72°C for 15 sec. The reac-
tion was concluded with 10 minutes 72°C as a final
extension step. The fluorescence of the accumulating
product was acquired for each cycle after an additional
5 seconds melting step at 78°C. Fluorescence monitor-
ing occurred at regular intervals during the annealing
phase and continuously throughout the melting phase.
The cycle at which fluorescence exceeded background,
the corrected threshold cycle (Ct), is negatively related
to the initial copy number in a given DNA sample. In
order to assess the relative copy numbers of
SELENBP1 each of the runs included a calibration
curve of both F8 and SELENBP1 using a DNA pool
which included four samples having the highest Ct
values. The F8 calibration curve was generated using
DNA concentrations of 1 × 109, 107, 105, 104 and 103
copies/μl. Quantification of each sample was obtained
by interpolation of Ct values from the generated
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standard curve using the Rotor-Gene software. Cor-
rected Ct values were calculated as previously
described [45] All assays included a no template nega-
tive control. All samples were run thrice. The pre-
sented results are the average of the three runs. Since
F8 is located on chromosome X, KCti values [45] of
the women were corrected accordingly.
Measurement of mRNA levels by RT-real time PCR
Quantitative RT-PCR was performed using the house-
keeping gene b-actin as an internal standard. b-actin
forward (TCCCTGGAGAAGAGCTACG) and reverse
(GTAGTTTCGTGGAT GCCACA) primers and
SELENBP1 forward (TCATCAGGGAAGGCTCTGTGA)
and reverse (GGGTGCCAAGAGAGAGCAGAA) pri-
mers were designed using the computer program
OLIGO based on the cDNA structure of the genes pub-
lished in Genebank.
SELENBP1 and b-actin first strand cDNA synthesis
was carried out in separate reactions. One μg RNA was
reverse transcribed into cDNA with ReverseiT 1st
Strand Synthesis Kit (ABgene, Surrey, UK) for 45 min at




Age Sex PMI pH DoI CoD Neuroleptics Age Sex PMI pH CoD
38 m 36.00 6.07 11 Hanging FD (25 mg, 3 weekly) 35 m 35.00 6.13 Coronary artery
atheroma
35 m 47.00 6.27 17 Perforated gastric ulcer FD (50 mg, 3 weekly) 38 m 44.00 6.19 Coronary artery
atheroma
47 m 41.50 6.52 21 Multiple injuries Chlorpromazine (400 mg daily), 48 m 24.00 6.37 Coronary artery
atheroma
53 m 43.00 6.23 7 Aspiration/food Haloperidol (150 mg, 2 weekly) 53 m 12.00 6.34 Pulmonary
thromboembolism
*Chlorpromazine (200 mg daily)
LAST RECORDED 14/6/88, 6 yrs prior to
death
69 m 44.50 6.38 47 Ischaemic heart disease Trifluoperazine HCl (5 mg, daily) 62 m 66.00 6.50 Acute myocardial infarct
61 m 37.50 6.46 38 Ischaemic heart disease *FD (62.5 mg, 2 weekly) 68 m 69.00 6.59 Coronary artery
atheroma
LAST RECORDED 22/1/92, 4 yrs prior to
death
65 F 50.00 6.35 18 Ruptured abdominal
aneurysm
FD (25 mg, 2 weekly), 66 F 43.00 6.37 Acute myocardial infarct
Haloperidol (5 mg, daily)
57 m 24.00 6.06 28 Coronary artery atheroma *FD (18.75 mg, 3 weekly), 57 m 27.00 6.43 Ischaemic heart disease
LAST RECORDED 29/1/93, 3 yrs prior to
death
69 m 48.00 6.44 6 Carbon monoxide
poisoning
*Haloperidol (7 mg, daily) 68 m 41.00 6.06 Aortic stenosis
LAST RECORDED 26/11/91, 5 yrs prior
to death
23 m 78.00 6.19 5 Multiple injuries *Haldol (150 mg, 4 weekly), 22 m 51.00 6.58 Exsanguination
LAST ADMINISTERED 3 weeks prior to
death
26 m 52.00 6.39 2 Carbon monoxide
poisoning
*Haldol (75 mg, 2 weekly), 25 m 35.00 6.15 Right ventricular
hypertrophy
LAST ADMINISTERED 2 days prior to
death
38 F 20.00 6.43 17 Burning FD (31.25 mg, 2 weekly) 36 F 60.00 6.40 Dilated cardiomyopathy
41 m 35.00 6.64 15 Hanging *FD (25 mg, ? weekly)
LAST RECORDED 15/11/88, 9 yrs prior
to death
47 F 50.00 6.31 20 Pneumonia *Respiridone (12 mg, daily), 47 F 24.00 5.89 Pulmonary embolus
LAST PRESCRIBED 6 months prior to
death
32 F 56.00 6.16 Coronary artery
atheroma
PMI = postmortem interval (hrs); DoI = duration of illness (yrs); CoD = cause of death;
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42°C in a final 20 μl reaction volume containing 1 μg
total cellular RNA. To obtain PCR results within the lin-
ear range of detection, the cDNA products were diluted
1:5 for both SELENBP1 and b-actin. Real-time quantita-
tive PCR was performed using Rotor Gene 3000 (Cor-
bett Research, Sydney, Australia). Reactions were carried
out in a final volume of 25 μl consisting of 2 μl purified
cDNA (SELENBP1 or b-actin), 250 nM each forward
and reverse primers and 12.5 bl ABsolute QPCR SYBR
Green Mix (ABgene, Surrey, UK) providing dNTPs, Taq
DNA polymerase and reaction buffer. SELENBP1 and b-
actin real-time PCR assays included an initial 15 min at
95°C step to activate Taq polymerase, followed by 40
cycles each comprising denaturation at 95°C for 15 sec,
annealing at 58°C for 20 seconds, and extension at 72°C
for 15 sec. The fluorescence of the accumulating pro-
duct was acquired at each cycle after an additional 5 sec-
onds melting step at 78°C. Each sample was run three
times. Final quantification of the mRNA levels was
carried out as previously described [46].
Statistical analysis
In the CNV determination procedure normalized Ct
values were not normally distributed. We thus com-
pared the distribution of SELENBP1 normalized Ct
values of schizophrenia patients in each of the three
cohorts with their respective controls using Kolmo-
gorov-Smirnov two-sample tests [47]. This nonpara-
metric test is sensitive to differences in parameters such
as location, dispersion and skewness between distribu-
tions [47]. Tests were performed using Systat 9.0 (Systat
Software, Inc., CA, USA). As mentioned above, the third
cohort was comprised of 26 triads of schizophrenia pro-
bands and their healthy parents. Each replicate of each
family is designated “sample”. A total of 78 samples (26
families × 3 replicates = 78 samples) were analysed
using the program PRIMER v6 (PRIMER-E Ltd, Ply-
mouth, UK). Each sample is represented as a point in a
three dimentional space defined by the SELENBP1 nor-
malized Ct values of each of the three family members.
We generated a dissimilarity matrix comprising of the
Euclidean distances between all possible pairwise sample
comparisons after applying a by total sample standardi-
zation [48]. Each of these dissimilarity coefficients repre-
sents the natural distance between two samples in the
distribution of SELENBP1 normalized Ct values among
family members [48]. To explore the “natural groupings”
of the 78 samples, we used a non-metric multi-dimen-
sional scaling (MDS) [49]. Our aim was to represent the
78 samples as points in low-dimensional space (i.e., 2-d)
such that the relative distances apart of all points are in
the same rank order as the relative dissimilarities (or
distances) of the samples as measured by the dissimilarly
matrix described above. A two-dimensional space
representation is considered excellent when the stress
value is smaller than 0.05 [50]. To test for significant
differences between families exhibiting de novo CNV of
the SELENBP1 locus and those in which CNV was
inherited we used an analysis of similarity test (ANO-
SIM) [48], analogous of the standard one-way analysis
of variance (ANOVA), but which operates on the dis-
similarity matrix described above.
Student’s t-test was used to compare SELENBP1
mRNA levels (relative to b-actin) between patients and
controls of the postmortem cerebellar cohort.
Results
We assessed the variation in copy number of the
SELENBP1 locus by real time PCR. Since there is no
‘wild type’ copy number of SELENBP1 to be used as a
reference we normalized the Ct obtained from each
sample by Ct of Factor 8 of the coagulation system, a
locus lacking CNV and hence expected to serve as a
normalizing reference for SELENBP1 copy number. We
performed 3 case-control comparisons of SELENBP1
CNV pattern. Cohort A: Blood DNA from 49 schizo-
phrenia patients and 49 healthy controls from Israeli
Bedouin origin. Since copy number of genes may vary
among tissues, we further investigated (Cohort B)
SELENBP1 copy number in age- sex- and postmortem
interval-matched cerebellar DNA samples from 14 schi-
zophrenia patients and 14 unrelated matched controls
originating from the Australian population [51]. Since a
CNV may either be de novo or be inherited we analyzed
CNV of the SELENBP1 locus in blood DNA from 26
Israeli Arab trios of schizophrenia probands and their
healthy parents (Cohort C) Schizophrenia-related differ-
ences in CNV of a specific locus have previously been
reported either in a qualitative manner [52] or in a sta-
tistical supported approach [53]. Here we report our
analysis in both ways.
The distribution of the SELENBP1 normalized Ct
values characterizing the schizophrenia patients was
right skewed in all three cohorts, indicating that the
number of cycles required to reach the same threshold
level was higher (lower copy number) among some of
the schizophrenia patients in each of these three unre-
lated sample sets. In cohort A one schizophrenia patient
exhibited drastic reduction and three patients had mod-
erately reduced gene copy number of the SELENBP1
locus which were not found in any of the control sub-
jects (Figure 1). This qualitative phenomenon did not
reflect an overall significant difference in the distribu-
tion of normalized Ct values of the SELENBP1 locus
between the schizophrenia patients and the healthy con-
trols. In the postmortem brain specimens (cohort B) a
markedly reduced copy number of SELENBP1 in two
schizophrenia specimens was observed (Figure 2). The
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Figure 1 A histogram of normalized cycle number required to reach a particular fluorescence threshold of the SELENBP1 gene in
blood DNA of schizophrenia patients and healthy controls. The distribution of the normalized Ct values of SELENBP1 in the patient group is
not significantly different from that of the control group (Kolmogorov-Smirnov two-sample test, p = 0.99). Circle denotes reduced copy number.
Figure 2 A histogram of normalized cycle number required to reach a particular fluorescence threshold of the SELENBP1 gene in
postmortem cerebellum DNA of schizophrenia patients. The distribution of the normalized Ct values of SELENBP1 in the patient group
differed significantly from that of the control group (Kolmogorov-Smirnov two-sample test, p = 0.038). Circle denotes reduced copy number.
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distribution of the normalized Ct values of SELENBP1
differed significantly between the patient and control
groups (Kolmogorov-Smirnov two-sample test, p =
0.038). To discern between inherited and de novo CNV
we analyzed the triads cohort (C) (Figure 3). The distri-
bution of the normalized Ct values of SELENBP1 in the
patient group differed significantly from that character-
izing the mothers (Kolmogorov-Smirnov two sample
test, p = 0.012), but not the fathers (Kolmogorov-Smir-
nov two-sample test, p = 0.87). Three patients showed a
drastically reduced copy number of SELENBP1, a phe-
nomenon not observed in any of the healthy parents.
Using an arbitrary difference of at least three normalized
Ct values between the patient and both of his/her par-
ents as de novo CNV, overall, six families of the 26
exhibited de novo CNV of the SELENBP1 locus. These
six families significantly differed from the other families
(ANOSIM test, Global r = 0.658, p = 0.001) (Figure 4).
Three of these families were those in whom the pro-
bands had the drastically reduced copy number of the
SELENBP1 locus. Taken together, rare reduction in
CNV of the SELENBP1 locus was found in patients but
not in controls of the three studied cohorts.
SELENBP1 mRNA levels in the postmortem cerebellar
specimens studied for CNV were about 16% significantly
reduced between patients and controls [controls: 0.170 +
0.02 Arbitrary Units (AU); patients 0.143 + 0.02 AU;
Student’s t-test, n = 14 in each diagnostic group, t =
-2.18, p = 0.037] with no correlation between
SELENBP1 Ct (reflecting copy number) and mRNA
levels in the patient group (r = -0.02).
Discussion
Recent evidence supported the involvement of CNV in
the etiology of complex disorders, in general, and in
schizophrenia, in particular [10,16,19-21,53-55]. How-
ever, most of these reports deal with whole genome
screens for CNV [16,19-21,54,55] and only few concen-
trate on specific loci [10,53]. The genome-wide assess-
ment has the obvious advantage of providing
concomitant evidence on multiple chromosomal loci.
However, the results of the genome-wide studies
[16,19-21] suggested that the concept of rare variants
with high penetrance rather than the “common disease-
common variant” hypothesis is more plausible to the
etiology of schizophrenia [56]. Whereas association of
common alleles could be identified by genome wide
approaches, rare alleles are identified by methods which
are not high throughput (such as re-sequencing of
genes). When focusing on a certain candidate locus in a
hypothesis-driven approach it is easier to identify rare
alleles and the results obtained do not need statistical
correction for multiple testing, possibly avoiding type-II
error [56].
Figure 3 A histogram of normalized cycle number required to reach a particular fluorescence threshold of the SELENBP1 gene in
blood DNA of schizophrenia probands and their healthy partents. The distribution of the normalized Ct values of SELENBP1 in the patient
group differed significantly from that of the mothers (Kolmogorov-Smirnov two-sample test, p = 0.012). Circle denotes reduced copy number.
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Here we present three replicating experiments demon-
strating notable reduction in copy number of the
SELENBP1 locus in nine of the patients of the three
cohorts (n = 89) but not in the healthy controls (n =
115) in line with previous observations of a comparable
extent of CNVs in this disorder [16,19]. Hence, rare
reduction in SELENBP1 CNVs associates with schizo-
phrenia providing proof of concept for our working
hypothesis.
Most of the probands in our triads cohort exhibited
CNV patterns similar to their healthy parents, implying
inherited CNV. The latter is in line with other studies
suggesting that most of the CNVs are stable [1,57].
However, six out of the 26 families exhibited de novo
CNV of the SELENBP1 locus, in three of whom the pro-
bands had drastically reduced copy number. Patients
with de-novo CNV differed significantly from the
mothers but not from the fathers. It is noteworthy that
new mutations are more common in sporadic cases of
disease than in cases where patients have family history
of the disease [58]. Since the reduced copy number was
totally attributed to de novo mutations in the triads it is
tempting to speculate that the same phenomenon
underlies the reduced copy number of the SELENBP1
locus among the patients in the two other sample sets.
This assumption is supported by Xu et al [21] who
showed that confirmed de novo CNV mutations are sig-
nificantly associated with schizophrenia.
CNV of a gene is among possible mechanisms for a
difference in its function [1,59,60]. The right-skewed
distribution reflecting reduced copy number of the
SELENBP1 locus in the postmortem cohort correlated
with 16% reduction of SELENBP1 mRNA levels of this
cohort. This result is in contrast with the previously
reported elevated mRNA levels of this gene in postmor-
tem frontal cortex of schizophrenia patients. The discre-
pancy may reflect differences in CNVs among tissues
[34,35] as well as documented tissue-specificity of
SELENBP1 mRNA expression [61-63]. Although
SELENBP1 mRNA levels of the two patients with the
drastically reduced copy number of the gene’s locus
were below the mean of the patients’ group, no linear
positive correlation between the copy number and
mRNA levels was obtained. It is possible that other
modes of association between SELENBP1 CNV and its
expression exist (e.g. a U-shaped relationship) since
balanced CNVs with no functional effect in a carrier
might create genomic instability only in future genera-
tions [64].
Conclusions and limitations
We show that the SELENBP1 locus which is present in
variable copy number in the general human population
exhibits reduced copy number in schizophrenia patients
from three different cohorts. Our cohorts are of a small
size but the replication in three different cohorts of two
different tissues compensate for this limitation. Although
no correlation was found between the copy number
change and the expression level of SELENBP1 it is
important to note that only part of SELENBP1 exon 12
was studied and therefore the borders of the SLENEBP1-
associated CNV are yet to be determined. Since this
CNV could encompass a much larger genomic region it
is possible that other factors would be affected by the
copy number reduction. The reduced copy number in
only 10% of the patients implies that other factors are
associated with the disease in most schizophrenia cases.
The general phenomenon of chromosomal instability in
brain disorders [16,21,65-67], especially deletions in schi-
zophrenia [10,19,20], raises the possibility that genome
integrity tends to be less protected in this disorder. If this
is true multiple regions could be prone to copy number
change in schizophrenia, which is in line with the multi-
factorial nature of the disease. Indeed, elevated induction
of common fragile sites, which are hot spots for chromo-
somal changes [68,69] have been reported in schizophre-
nia patients [70,71]. Taken together, our study underlines
replicated association of reduced copy number of a given
locus with schizophrenia. Further studies towards identi-
fying candidate factors in this locus to contribute to the
schizophrenia phenotype are warranted.
Figure 4 Two-dimensional representation of non-metric
multidimensional scaling (MDS) ordination of the triads cohort.
The cohort consisted of 78 samples (26 trios of schizophrenia
probands and their health parents X 3 replicates = 78 samples). The
analysis is based on the dissimilarity matrix generated by calculating
the Euclidian distance between each of the possible pairwise
sample comparisons. Stress value: 0.01; A two-dimensional space
representation is considered excellent when the stress value is
smaller than 0.05 [50]. ANOSIM test, Global r = 0.658, p = 0.001.
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